Identifying barriers to cellular therapies for multiple myeloma patients
Prospective Multi-Center Study to Identify Barriers to Cellular Therapies in Patients With Plasma Cell Disorders PROACT PCD
This study is trying to find out what challenges people with relapsed or refractory multiple myeloma and their doctors face when trying to access new cell therapies like transplants and CAR T-cell treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Drugs / interventions | chimeric antigen receptor |
| Locations | 7 sites (Basking Ridge, New Jersey and 6 other locations) |
| Trial ID | NCT06126341 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather insights from patients with relapsed/refractory Multiple Myeloma and their healthcare providers regarding the use of hematopoietic cell transplantation and BCMA CAR T-cell therapy. Participants will engage in discussions and complete assessments related to their experiences and the challenges they face in accessing these therapies. The study will focus on understanding the barriers that may prevent effective treatment for this patient population.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18-80 with a diagnosis of Multiple Myeloma who have undergone at least two lines of prior therapy and are expected to start a new line of treatment within the next year.
Not a fit: Patients with active CNS disease or those who already have a definitive treatment plan may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify and address barriers to accessing advanced therapies for multiple myeloma, potentially improving patient outcomes.
How similar studies have performed: While this study focuses on identifying barriers, similar studies have shown success in improving access to therapies for other conditions, suggesting potential for impactful findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patient * Diagnosis of Multiple Myeloma after January 1, 2017. * Karnofsky Performance Status \> 70% * ≥ 2 lines of prior therapy * Anticipated to start new a line of therapy for RRMM within the next 12 months * Age 18-80 years of age. * English or Spanish speaking. * Willing to provide informed consent * Willing to perform study procedures. Physician Investigator * Be a Co-Investigator * Agree to comply with study procedures Exclusion Criteria: Patient * Active CNS disease * Patients who already have a definitive plan are to be excluded
Where this trial is running
Basking Ridge, New Jersey and 6 other locations
- Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey, United States (Recruiting)
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey, United States (Recruiting)
- Memorial Sloan Kettering Bergen — Montvale, New Jersey, United States (Recruiting)
- Memorial Sloan Kettering Commack — Commack, New York, United States (Recruiting)
- Memorial Sloan Kettering Westchester — Harrison, New York, United States (Recruiting)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (Recruiting)
- Memorial Sloan Kettering Nassau — Uniondale, New York, United States (Recruiting)
Study contacts
- Principal investigator: Heather Landau, MD — Memorial Sloan Kettering Cancer Center
- Study coordinator: Heather Landau, MD
- Email: ABMTTrials@mskcc.org
- Phone: 646-608-3740
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.